News Agency
Men's Weekly

OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002

  • Written by PR Newswire

SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain in Australia with Novotech. The Phase 2a trial consists of an open label...

Read more: OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients...

The Role of Stainless Steel Suppliers in Australia’s Industry

Stainless steel has become a cornerstone of modern industry, valued for its strength, durability, and resistance to corrosion. From construction and manufacturing to kitchenware and medical equipment, stainless steel plays a vital role in countless applications. Central to this supply... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion